sar425899 sanofi glp-1 glucagon dual agonist Focus on Glucagon-like Peptide- 1 Target: Drugs Approved or Designed to Treat Obesity Oral GLP-1-Based Therapeutics in the

Description

Although use of GLP-1RAs does not increase the risk of severe hypoglycaemia, 10 it may elevate the risk of hypoglycaemia caused by insulin and sulfonylureas if prescribed with these agents

The widespread use of GLP-1 therapies, particularly in obesity, has raised questions about appropriate prescribing, long-term safety, and equitable access

Patients on GLP-1RAs are considered at-risk, meaning they also should: Follow more frequent reexamination intervals Receive individualized risk counseling regarding ocular risks Get collaborative care with providers managing their diabetes and other systemic conditions Doctors of optometry have to be aware, Dr

Al-Aly says

A summary of the key preclinical and clinical findings on GLP-1RAs and DPP-4is in neuropathic pain models is presented in Table 1, highlighting their proposed mechanisms of action and therapeutic outcomes across various studies